Key Drivers
- Zero revenue
- High cash burn
- Strong liquidity
AIAI Summary
Reframe ORIC as a clinical‑stage story: program risk for rinzimetostat and other assets is declining with near‑term dose/combination readouts and AACR visibility potentially de‑risking value, but the company's <1‑year runway makes imminent financing the single decisive event that will determine dilution and upside. Monitor upcoming dose‑optimization readouts and any non‑dilutive partnership or financing terms as the primary triggers that will materially change the investment outcome.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Zero revenue
- •High cash burn
- •Strong liquidity
ORIC is a pre-revenue, high-R&D biotech with zero sales, sustained ~-$110M annual cash burn against $45.7M cash (≈41% of one year's OCF), large invested assets and very low liabilities/no debt—creating strong balance-sheet liquidity but a serious near-term funding gap for operations.
Price Behavior
Key Price Behavior Insights:
- •Range-bound
- •Support holds
- •Weak momentum
Stock traded rangebound over the last month (opened ~$11.11, closed ~$11.16) with firm support near $11.00, a failed follow-through after a sharp upside spike to $13.88, and key resistances at ~$12.60 and $13.5–$13.9 that must clear to resume a bullish trend.
Sharp upside spike to $13.88 (over 20% rally from support) followed by steady pullback
Sentiment & News
Key News Insights:
- •Rinzimetostat progress
- •Analyst upside
- •Golden cross
Oric Pharmaceuticals showed coordinated clinical progress for rinzimetostat, growing analyst confidence and bullish technical momentum, pointing to heightened investor interest and Phase‑3 planning for prostate and lung programs.
These clinical updates, analyst support and technical strength should boost investor attention and may drive share appreciation ahead of upcoming clinical catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings